NHS to receive £8m from Aspen over anti-competitive practices
15-08-2019
CMA accuses hydrocortisone suppliers of anti-competitive behaviour
04-03-2019
StockStudio / Shutterstock.com
The UK Competition and Markets Authority (CMA) has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Phenytoin, pricing, CMA, Competition and Markets Authority, epilepsy, Pfizer, Flynn Pharma, Competition Appeal Tribunal
